Madrigal Pharmaceuticals, Inc. (MDGL)
Madrigal Pharmaceuticals, Inc., a biopharmaceutical company, focuses on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH) in the United States. It offers Rezdiffra, a liver-directed thyroid hormone receptor beta agonist for treating MASH. The company was founded in 2016 and is headquartered in West Conshohocken, Pennsylvania.
- Symbol
- MDGL
- Exchange
- Nasdaq
- Sector
- Healthcare
- Industry
- Biotechnology
- Market cap
- $11.98B
- 52 week range
- 393.61 - 615
Valuation
- Share price
- $513.02 (close of 2026-09-23)
- P/E (TTM)
- -37.11x
- Price to book
- 22.88x
- Price to free cash flow
- -58.08x
- Enterprise value
- $12.04B
- Book value per share
- $22.68
Price performance
| Period | Change |
|---|
| 1 day | -1.71% |
| 5 days | -1.96% |
| 1 month | -0.72% |
| 3 months | -0.08% |
| 6 months | +14.59% |
| Year to date | -11.90% |
| 1 year | +15.72% |
| 3 years | +234.56% |
| 5 years | +503.84% |
| 10 years | +4303.61% |
| All time | +61.25% |
Profitability and growth
- Return on equity
- -47.83%
- Return on invested capital
- -39.93%
- Return on assets
- -22.89%
- Return on capital employed
- -31.61%
- Gross margin
- 53.60%
- Net margin
- -30.08%
- EBITDA margin
- -31.16%
- Revenue growth
- 432.05%
- Net income growth
- 38.12%
- Free cash flow growth
- 58.42%
Cash flow and balance sheet
- Free cash flow yield (TTM)
- -1.72%
- Current ratio
- 3.20x
- Net debt to EBITDA
- -0.19x
Latest reported year
- Period end
- 2025-12-31
- Fiscal year
- 2025
- Revenue
- $958.40M
- Cost of revenue
- $444.67M
- Gross profit
- $513.73M
- EBITDA
- $-298.59M
- Net income
- $-288.28M
- Earnings per share
- $-12.85
- Shares outstanding
- 22.43M
Income statement by year
| Period end | Revenue | Gross profit | Net income | EPS |
|---|
| 2025-12-31 | $958.40M | $513.73M | $-288.28M | $-12.85 |
| 2024-12-31 | $180.13M | $173.90M | $-465.89M | $-21.90 |
| 2023-12-31 | - | - | $-373.63M | $-19.99 |
| 2022-12-31 | - | - | $-295.35M | $-17.23 |
| 2021-12-31 | - | - | $-241.85M | $-14.63 |
| 2020-12-31 | - | - | $-202.24M | $-13.09 |
| 2019-12-31 | - | - | $-83.95M | $-5.45 |
| 2018-12-31 | - | - | $-32.81M | $-2.22 |
| 2017-12-31 | - | - | $-31.15M | $-2.54 |
| 2016-12-31 | - | - | $-26.39M | $-5.07 |
Margins and returns by year
| Period end | Gross margin | Net margin | Return on equity | Return on capital |
|---|
| 2025-12-31 | 53.60% | -30.08% | -47.83% | -39.93% |
| 2024-12-31 | 96.54% | -258.64% | -61.76% | - |
| 2023-12-31 | - | - | -92.18% | - |
| 2022-12-31 | - | - | -149.63% | - |
| 2021-12-31 | - | - | -123.32% | -150.95% |
| 2020-12-31 | - | - | -84.28% | -110.67% |
| 2019-12-31 | - | - | -20.15% | -25.63% |
| 2018-12-31 | - | - | -6.88% | -9.70% |
| 2017-12-31 | - | - | -17.09% | - |
| 2016-12-31 | - | - | -72.47% | - |
Cash and debt by year
| Period end | Cash | Debt |
|---|
| 2025-12-31 | $198.69M | $339.88M |
| 2024-12-31 | $931.25M | $117.57M |
| 2023-12-31 | $634.13M | $115.48M |
| 2022-12-31 | $358.77M | $49.29M |
| 2021-12-31 | $36.27M | - |
| 2020-12-31 | $54.00M | - |
| 2019-12-31 | $46.70M | - |
| 2018-12-31 | $57.38M | - |
| 2017-12-31 | $191.53M | - |
| 2016-12-31 | $40.50M | - |
Free cash flow by year
| Period end | Free cash flow | Stock-based compensation |
|---|
| 2025-12-31 | $-190.02M | $98.13M |
| 2024-12-31 | $-457.03M | $79.88M |
| 2023-12-31 | $-325.71M | $49.73M |
| 2022-12-31 | $-225.07M | $31.63M |
| 2021-12-31 | $-184.13M | $26.87M |
| 2020-12-31 | $-157.90M | $20.73M |
| 2019-12-31 | $-41.80M | $22.76M |
| 2018-12-31 | $-25.53M | $13.49M |
| 2017-12-31 | $-22.44M | $3.25M |
| 2016-12-31 | $-17.61M | $7.93M |
Investor relations
Next earnings report
- Next confirmed report
- 2026-11-03
- Consensus EPS estimate
- $1.00
Past earnings dates
| Reported | Fiscal period | EPS estimate |
|---|
| 2026-07-30 | Jun/2026 | - |
| 2026-05-06 | - | - |
| 2026-02-19 | - | - |
| 2025-11-04 | - | - |
| 2025-08-05 | - | - |
| 2025-05-01 | - | - |
| 2025-02-26 | - | - |
| 2024-10-31 | - | - |
Filings and sources
- Company website
- madrigalpharma.com
- SEC filings
- 10-K, 10-Q and 8-K on EDGAR
- Earnings calendar
- All upcoming reports
Similar companies
Vertex Pharmaceuticals Inc (VRTX) · Regeneron Pharmaceuticals, Inc. (REGN) · Moderna, Inc. (MRNA) · Incyte Corp (INCY) · Bio-Techne Corp (TECH) · Thermo Fisher Scientific Inc. (TMO) · Danaher Corp (DHR) · IQVIA Holdings Inc. (IQV)
All Healthcare companies
Understanding these figures
Price-to-earnings ratio · Discounted cash flow · Free cash flow · Earnings per share · Return on equity · Gross margin vs net margin · Reading a balance sheet · Debt and leverage · Dividend yield · Insider transactions and Form 4 · How to read a stock chart
Explore
Company directory · S&P 500 heatmap · Earnings calendar · Super investor holdings · Congress trades